Revascor was never intended as a stand alone treatment. Instead it will likely be used alongside other agents that reduce non-fatal recurrent events if approved. Other treatments will be used to reduce non-fatal recurrent events (think maximal therapy), while our treatment will be used to reduce mortality rates, and is the only treatment currently shown to reduce mortality rates btw.
The reason why we didn't reduce non-fatal recurrent decompensated events is probably because patients in the placebo group were receiving maximal care or because our treatment doesn't reduce these events. We won't know until we get a look at the data, but I can see this as becoming part of the litany of treatments offered to heart failure patients, and it is sorely needed.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Heart Failure Results
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-343
-
- There are more pages in this discussion • 680 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
96.0¢ |
Change
0.010(1.05%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
94.5¢ | 97.5¢ | 94.0¢ | $2.076M | 2.161M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 162826 | 96.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 28820 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 162826 | 0.960 |
6 | 80489 | 0.955 |
6 | 62777 | 0.950 |
1 | 5500 | 0.945 |
9 | 112571 | 0.940 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 28820 | 3 |
0.975 | 27691 | 4 |
0.980 | 60702 | 4 |
0.985 | 70702 | 3 |
0.990 | 93055 | 5 |
Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |